176 related articles for article (PubMed ID: 31035298)
1. [Procedural guideline for Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma (version 5)].
Verburg FA; Schmidt M; Kreissl MC; Grünwald F; Lassmann M; Hänscheid H; Hohberg M; Luster M; Dietlein M
Nuklearmedizin; 2019 Jun; 58(3):228-241. PubMed ID: 31035298
[TBL] [Abstract][Full Text] [Related]
2. [Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma].
Verburg FA; Grünwald F; Lassmann M; Hänscheid H; Luster M; Dietlein M
Nuklearmedizin; 2018 Aug; 57(4):124-136. PubMed ID: 30125925
[TBL] [Abstract][Full Text] [Related]
3. [Guideline for Radioiodine Therapy for Benign Thyroid Diseases (6/2022 - AWMF No. 031-003)].
Dietlein M; Grünwald F; Schmidt M; Kreissl MC; Luster M; ; ; ;
Nuklearmedizin; 2024 Feb; 63(1):8-20. PubMed ID: 37871629
[TBL] [Abstract][Full Text] [Related]
4. [Radioiodine therapy for benign thyroid diseases (version 5). German Guideline].
Dietlein M; Grünwald F; Schmidt M; Schneider P; Verburg FA; Luster M
Nuklearmedizin; 2016 Dec; 55(6):213-220. PubMed ID: 27922153
[TBL] [Abstract][Full Text] [Related]
5. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4].
Dietlein M; Eschner W; Grünwald F; Lassmann M; Verburg FA; Luster M
Nuklearmedizin; 2016 Jun; 55(3):77-89. PubMed ID: 27350004
[TBL] [Abstract][Full Text] [Related]
6. The case for obtaining a diagnostic whole-body scan prior to iodine 131 treatment of differentiated thyroid cancer.
McDougall IR
Thyroid; 2009 Aug; 19(8):811-3. PubMed ID: 19645613
[No Abstract] [Full Text] [Related]
7. [Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3)].
Dietlein M; Dressler J; Eschner W; Grünwald F; Lassmann M; Leisner B; Luster M; Reiners C; Schicha H; Schober O; ;
Nuklearmedizin; 2007; 46(5):206-12. PubMed ID: 17938756
[TBL] [Abstract][Full Text] [Related]
8. [Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer].
Franzius C; Dietlein M; Biermann M; Frühwald M; Linden T; Bucsky P; Reiners C; Schober O
Nuklearmedizin; 2007; 46(5):224-31. PubMed ID: 17938759
[TBL] [Abstract][Full Text] [Related]
9. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases.
Ruhlmann M; Jentzen W; Ruhlmann V; Pettinato C; Rossi G; Binse I; Bockisch A; Rosenbaum-Krumme S
J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981
[TBL] [Abstract][Full Text] [Related]
10. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)].
Dietlein M; Dressler J; Farahati J; Grünwald F; Leisner B; Moser E; Reiners C; Schicha H; Schober O;
Nuklearmedizin; 2004 Aug; 43(4):115-20. PubMed ID: 15316577
[TBL] [Abstract][Full Text] [Related]
11. The low utility of pretherapy scans in thyroid cancer patients.
Schlumberger MJ; Pacini F
Thyroid; 2009 Aug; 19(8):815-6. PubMed ID: 19645614
[No Abstract] [Full Text] [Related]
12. Our solution for fusion of simultaneusly acquired whole body scintigrams and optical images, as usesful tool in clinical practice in patients with differentiated thyroid carcinomas after radioiodine therapy. A useful tool in clinical practice.
Matovic M; Jankovic M; Barjaktarovic M; Jeremic M
Hell J Nucl Med; 2017; 20 Suppl():159. PubMed ID: 29324929
[TBL] [Abstract][Full Text] [Related]
13. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.
Maruoka Y; Abe K; Baba S; Isoda T; Sawamoto H; Tanabe Y; Sasaki M; Honda H
Radiology; 2012 Dec; 265(3):902-9. PubMed ID: 23012466
[TBL] [Abstract][Full Text] [Related]
14. Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?
Schaap J; Eustatia-Rutten CF; Stokkel M; Links TP; Diamant M; van der Velde EA; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2002 Jul; 57(1):117-24. PubMed ID: 12100079
[TBL] [Abstract][Full Text] [Related]
15. Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
Campennì A; Pignata SA; Baldari S
Endocrine; 2015 Nov; 50(2):516-8. PubMed ID: 25471282
[TBL] [Abstract][Full Text] [Related]
16. [Utility and limits of nuclear medicine in the follow-up of differentiated thyroid carcinoma].
Chiti A; Orunesu E; Rodari M
Ann Ital Chir; 2006; 77(3):215-22. PubMed ID: 17137036
[TBL] [Abstract][Full Text] [Related]
17. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].
Dietlein M; Dressler J; Eschner W; Grünwald F; Lassmann M; Leisner B; Luster M; Moser E; Reiners C; Schicha H; Schober O; ;
Nuklearmedizin; 2007; 46(5):213-9. PubMed ID: 17938757
[TBL] [Abstract][Full Text] [Related]
18. Differentiated thyroid carcinoma referred for radioiodine therapy.
Al-Balawi IA; Meir HM; Yousef MK; Nayel HA; Al-Mobarak MF
Saudi Med J; 2001 Jun; 22(6):497-503. PubMed ID: 11426239
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of iodine-123 whole-body scan in planning iodine-131 treatment of the differentiated thyroid carcinoma in children and adolescence.
Villani MF; Grossi A; Cassano B; Pizzoferro M; Ubertini G; Longo M; Garganese MC
Nucl Med Commun; 2018 Dec; 39(12):1121-1128. PubMed ID: 30260898
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of bone metastases with radium-223. German guidelines].
Pöppel TD; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Scheidhauer K; Schenck M; Sonnenschein W; Gabriel M
Nuklearmedizin; 2016 Sep; 55(5):177-86. PubMed ID: 27417067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
